Abstract
Background
In the last decade, there has been an increased interest toward fat tissue as an endocrine organ that secretes many cytokines and bioactive mediators that play a role in insulin sensitivity, inflammation, coagulation and the pathogenesis of atherosclerosis. The aim of this study was to investigate classical (adiponectin, leptin, resistin) and new (chemerin, vaspin, omentin) adipocytokine levels in subjects with prediabetes [impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT)] and obese subjects with normoglycemia.
Methods
In this study, 80 patients with a mean age of 50.4 ± 10.6 years were recruited, divided into two groups with similar age and body mass index (BMI) – with obesity and normoglycemia (n = 41) and with obesity and prediabetes (n = 39).
Results
Serum adiponectin levels were significantly higher in subjects with normoglycemia compared to patients with prediabetes. Adiponectin has a good discriminating power to distinguish between patients with and without insulin resistance in our study population [area under the curve (AUC) = 0.728, p = 0.002]. Other adipocytokine levels were not significantly different between the two groups. The patients with metabolic syndrome (MetS) had significantly lower levels of leptin compared to those without MetS (33.03 ± 14.94 vs. 40.24 ± 12.23 ng/mL) and this difference persisted after adjustment for weight and BMI. Receiver operating characteristic (ROC) analysis showed that low serum leptin can predict the presence of MetS (p = 0.03), AUC = 0.645.
Conclusion
Serum adiponectin is statistically higher in patients with normoglycemia compared to those with prediabetes and has a predictive value for distinguishing between patients with and without insulin resistance in the studied population. Serum leptin has a good predictive value for distinguishing between patients with and without MetS in the studied population.
Author Statement
Research funding: This study was conducted with the financial support of Medical University Sofia, funder id: 10.13039/100009086; Medical Sciences Council – Project 4651/22.07.2015; Contract 3-C/01.12.2015. The sponsor had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
Conflict of interest: The authors declare that they have no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. All authors have read and approved the final article.
Informed consent: Informed consent has been obtained from all individuals.
Ethical approval: The research related to human use complies with all the relevant National Regulations and Institutional Policies and was performed in accordance with the tenets of the Helsinki Declaration. The project was approved by the University ethics committee for clinical projects.
References
[1] Fantuzzi G, Mazzone T. Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol. 2007;27:996–1003.10.1161/ATVBAHA.106.131755Search in Google Scholar PubMed
[2] Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997;46:3–10.10.2337/diab.46.1.3Search in Google Scholar
[3] Filková M, Haluzík M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol. 2009;133:157–70.10.1016/j.clim.2009.07.013Search in Google Scholar PubMed
[4] Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol. 2012;165:622–32.10.1111/j.1476-5381.2011.01369.xSearch in Google Scholar PubMed PubMed Central
[5] Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab. 2010;21:660–7.10.1016/j.tem.2010.08.001Search in Google Scholar PubMed
[6] Schaffler A, Neumeier M, Herfarth H, Furst A, Scholmerich J, Buchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta. 2005;1732:96–102.10.1016/j.bbaexp.2005.11.005Search in Google Scholar PubMed
[7] Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab. 2006;290:E1253–61.10.1152/ajpendo.00572.2004Search in Google Scholar PubMed
[8] Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun. 2011;408:339–43.10.1016/j.bbrc.2011.04.039Search in Google Scholar PubMed
[9] Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun. 2010;393:668–72.10.1016/j.bbrc.2010.02.053Search in Google Scholar PubMed
[10] Kadoglou NP, Gkontopoulos A, Kapelouzou A, Fotiadis G, Theofilogiannakos EK, Kottas G, et al. Serum levels of vaspin and visfatin in patients with coronary artery disease – Kozani study. Clin Chim Acta. 2011;412:48–52.10.1016/j.cca.2010.09.012Search in Google Scholar PubMed
[11] Kobat MA, Celik A, Balin M, Altas Y, Baydas A, Bulut M, et al. The investigation of serum vaspin level in atherosclerotic coronary artery disease. J Clin Med Res. 2012;4:110–3.10.4021/jocmr841wSearch in Google Scholar PubMed PubMed Central
[12] Aust G, Richter O, Rohm S, Kerner C, Hauss J, Klöting N, et al. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis. 2009;204:262–6.10.1016/j.atherosclerosis.2008.08.028Search in Google Scholar PubMed
[13] Arancibia C, Galgani J, Valderas JP, Morales M, Santos JL, Pollak F. Evaluation of serum insulin levels after an oral glucose load for the diagnosis of insulin resistance. Rev Med Chil. 2014;142:1106–12.10.4067/S0034-98872014000900003Search in Google Scholar PubMed
[14] Ascaso J, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care. 2003;26:3320–5.10.2337/diacare.26.12.3320Search in Google Scholar PubMed
[15] Huang S, Zou D, Peng W, Jiang X, Shao K, Xia L, et al. The prediction roles of asymmetric dimethyl-arginine, adiponectin and apelin for macroangiopathy in patients with impaired glucose regulation. Ann Endocrinol (Paris). 2016;77:633–40.10.1016/j.ando.2016.03.004Search in Google Scholar PubMed
[16] Lai H, Lin N, Xing Z, Weng H, Zhang H. Association between the level of circulating adiponectin and prediabetes: a meta-analysis. J Diabetes Investig. 2015;6:416–29.10.1111/jdi.12321Search in Google Scholar PubMed PubMed Central
[17] Stojanović S, Ilić MD, Ilić S, Petrović D, Djukić S. The significance of adiponectin as a biomarker in metabolic syndrome and/or coronary artery disease. Vojnosanit Pregl. 2015;72:779–84.10.2298/VSP140531067SSearch in Google Scholar PubMed
[18] Jiang Y, Owei I, Wan J, Ebenibo S, Dagogo-Jack S. Adiponectin levels predict prediabetes risk: the Pathobiology of Prediabetes in A Biracial Cohort (POP-ABC) study. BMJ Open Diabetes Res Care. 2016;4:e000194.10.1136/bmjdrc-2016-000194Search in Google Scholar PubMed PubMed Central
[19] Yamamoto S, Matsushita Y, Nakagawa T, Hayashi T, Noda M, Mizoue T. Circulating adiponectin levels and risk of type 2 diabetes in the Japanese. Nutr Diabetes. 2014;4:e130.10.1038/nutd.2014.27Search in Google Scholar PubMed PubMed Central
[20] Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Valentí V, Moncada R, et al. Peripheral mononuclear blood cells contribute to the obesity-associated inflammatory state independently of glycemic status: involvement of the novel proinflammatory adipokines chemerin, chitinase-3-like protein 1, lipocalin-2 and osteopontin. Genes Nutr. 2015;10:460.10.1007/s12263-015-0460-8Search in Google Scholar PubMed PubMed Central
[21] Fatima S, Butt Z, Bader N, Pathan AZ, Hussain S, Iqbal NT. Role of multifunctional chemerin in obesity and preclinical diabetes. Obes Res Clin Pract. 2015;9:507–12.10.1016/j.orcp.2015.01.004Search in Google Scholar PubMed
[22] Li Y, Shi B, Li S. Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: a meta-analysis. PLoS One. 2014;9:e113915.10.1371/journal.pone.0113915Search in Google Scholar PubMed PubMed Central
[23] de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007;56:1655–61.10.2337/db06-1506Search in Google Scholar PubMed
[24] Tan B, Adya R, Farhatullah S, Lewandowski KC, O’Hare P, Lehnert H. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome. Diabetes 2008;57:801–8.10.2337/db07-0990Search in Google Scholar PubMed
[25] Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis. 2011 219:811–8.10.1016/j.atherosclerosis.2011.08.017Search in Google Scholar PubMed
[26] Yoo HJ, Hwang SY, Hong HC, Choi HY, Yang SJ, Seo JA, et al. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol. 2011;10:103.10.1186/1475-2840-10-103Search in Google Scholar PubMed PubMed Central
[27] Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract. 2010;88:29–33.10.1016/j.diabres.2010.01.013Search in Google Scholar PubMed
[28] Akour A, Kasabri V, Boulatova N, Bustanji Y, Naffa R, Hyasat D, et al. Levels of metabolic markers in drug-naive prediabetic and type 2 diabetic patients. Acta Diabetol. 2017;54:163–70.10.1007/s00592-016-0926-1Search in Google Scholar PubMed
[29] Herder C, Ouwens DM, Carstensen M, Kowall B, Huth C, Meisinger C, et al. Adiponectin may mediate the association between omentin, circulating lipids and insulin sensitivity: results from the KORA F4 study. Eur J Endocrinol. 2015;172:423–32.10.1530/EJE-14-0879Search in Google Scholar PubMed
[30] Jian W, Peng W, Xiao S, Li H, Jin J, Qin L, et al. Role of serum vaspin in progression of type 2 diabetes: a 2-year cohort study. PLoS One. 2014;9:e94763.10.1371/journal.pone.0094763Search in Google Scholar PubMed PubMed Central
[31] Ye Y, Hou XH, Pan XP, Lu JX, Jia WP. Serum vaspin level in relation to postprandial plasma glucose concentration in subjects with diabetes. Chin Med J (Engl). 2009;122:2530–3.Search in Google Scholar
[32] Feng R, Wang C, Sun C-H, Guo F-C, Zhao C, Li Y. Vaspin in newly and previously diagnosed Chinese type 2 diabetic females: a case-control study. Asian Biomedicine. 2011;5:525–9.10.5372/1905-7415.0504.069Search in Google Scholar
[33] Youn BS, Klöting N, Kratzsch J, Lee N, Park JW, Song ES, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008;57:372–7.10.2337/db07-1045Search in Google Scholar PubMed
©2018 Walter de Gruyter GmbH, Berlin/Boston
